VIVEbiotech expanded its lentiviral vector manufacturing toolkit with EvoLVcell, a stable producer cell line generation platform aimed at cutting batch-to-batch variability. The platform is designed to reduce impurities and improve vector quality by leveraging fully characterized monoclonal packaging cell lines, with developers adding their transgenic element instead of running repeated transfection steps. VIVEbiotech said it can deliver a prototype cell line in about three months, using rapid proof-of-concept and yield assessment to create a go/no-go inflection point early in the manufacturing development cycle. The company’s positioning targets the operational fragility that can slow gene therapy development when plasmid and transfection supply chains become constraints. For gene therapy CDMOs and developers, the emphasis on predictability and fewer process impurities aligns with the industry’s push to compress timelines while maintaining GMP-consistent outputs.